An FDA review concluded that patients should not stop taking bisphosphonates because there is no clear link between the osteoporosis treatments and irregular heart rhythms. The agency examined studies involving seven approved brands in the drug class, including Merck & Co.'s Fosamax and Roche Holding's Boniva, as well as Novartis' Aredia and Reclast. The three companies said the FDA's finding is consistent with their data.

Full Story:

Related Summaries